Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!
AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.
Salesforce (CRM): Insider Buys, AI Clouds, and Customer Armies — Should You Join the Ride?
Salesforce insiders are buying, AI is booming, and institutions are all-in. But is CRM stock really ready to rebound — or just blowing more cloud smoke? ☁️💸
Quick links
Search
Privacy Policy
Refund Policy
Shipping Policy
Terms of Service
Contact us
About us
FUNanc!al distills the fun in finance and the finance in fun, makes news personal, and helps all reach happiness.
